Status:
COMPLETED
Total Hemihepatic Vascular Exclusion in Hepatectomy in Hepatocellular Carcinoma Treatment
Lead Sponsor:
Eastern Hepatobiliary Surgery Hospital
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Total hemihepatic vascular exclusion(THHVE),completely isolates the right or left hemiliver ipsilateral to the lesion that requires resection from the systemic circulation,has the advantage of prevent...
Detailed Description
The amount of blood loss and blood transfusion in Hepatectomy have a detrimental effect on the prognosis for Hepatocellular carcinoma(HCC).Intraoperative bleeding remains a major concern during liver ...
Eligibility Criteria
Inclusion
- 5
- Understanding and being willing to sigh the informed consent form.
- Aged 18-75years.
- Corresponding to diagnostic standards of HCC, without any adjuvant therapy,tumor or multiple tumors located in right or left liver lobe.
- The function of heart, lung ,renal is well,without any surgery contraindication.
- KPS score≥60分
- Liver function in the Child-Pugh classification is A or B.
- Tumor AJCC stage isⅠorⅡ.
Exclusion
- cannot be follow-up
- liver function in the Child-Pugh classification is C.
- with tumor thrombus in the hepatic vein or main trunk of portal vein
- with extrahepatic metastasis
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00827047
Start Date
January 1 2009
End Date
December 1 2012
Last Update
April 1 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Eastern hepatobilliary surgery hospital
Shanghai, Shanghai Municipality, China